Zynerba Pharmaceuticals (GB:0M40)
LSE:0M40
UK Market

Zynerba Pharmaceuticals Stock Analysis & Ratings

GB:0M40 Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.00 - $0.00
Previous Close$0.98
VolumeN/A
Average Volume (3M)629.00
Market Cap$42.85M
P/E RatioN/A
Beta1.93
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score3
EPS (TTM)0.00


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

GB:0M40 FAQ

What was Zynerba Pharmaceuticals’s price range in the past 12 months?
Zynerba Pharmaceuticals lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Zynerba Pharmaceuticals’s market cap?
    Zynerba Pharmaceuticals’s market cap is $42.85M.
      What is Zynerba Pharmaceuticals’s price target?
      The average price target for Zynerba Pharmaceuticals is $8.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $8.00 ,the lowest forecast is $8.00. The average price target represents 713.84% Increase from the current price of $0.983.
        What do analysts say about Zynerba Pharmaceuticals?
        Zynerba Pharmaceuticals’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Zynerba Pharmaceuticals’s upcoming earnings report date?
          Zynerba Pharmaceuticals’s upcoming earnings report date is Aug 03, 2022 which is in 75 days.
            How were Zynerba Pharmaceuticals’s earnings last quarter?
            Zynerba Pharmaceuticals released its earnings results on May 16, 2022. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.228 by $0.018.
              Is Zynerba Pharmaceuticals overvalued?
              According to Wall Street analysts Zynerba Pharmaceuticals’s price is currently Undervalued.
                Does Zynerba Pharmaceuticals pay dividends?
                Zynerba Pharmaceuticals does not currently pay dividends.
                What is Zynerba Pharmaceuticals’s EPS estimate?
                Zynerba Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Zynerba Pharmaceuticals have?
                Zynerba Pharmaceuticals has 43,600,000 shares outstanding.
                  What happened to Zynerba Pharmaceuticals’s price movement after its last earnings report?
                  Zynerba Pharmaceuticals reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.228. Following the earnings report the stock price went down -23.932%.
                    Which hedge fund is a major shareholder of Zynerba Pharmaceuticals?
                    Currently, no hedge funds are holding shares in GB:0M40

                    ---

                    Zynerba Pharmaceuticals Stock Analysis

                    Smart Score
                    3
                    Underperform
                    1
                    2
                    3
                    4
                    5
                    6
                    7
                    8
                    9
                    10
                    Price Target
                    $8.00
                    ▲(713.84% Upside)
                    Moderate Buy
                    The Zynerba Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Zynerba Pharmaceuticals

                    Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

                    ---
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Marinus
                    Pfizer
                    Ovid Therapeutics
                    Acorda Therapeutics

                    Popular Stocks

                    ---
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis